GAITHERSBURG, Md.--Gene Logic here announced that it was issued a US patent for an enzyme-based genomics technology, "differential display," in which restriction enzymes reveal differences in gene expression among various tissue samples. Gene Logic said that methods based on the approach covered by the patent are more suitable for industrial-scale operations than a differential display method that doesn't require restriction enzymes.
Gene Logic holds an exclusive worldwide license on the patent from the New York Blood Center, whose broad patent covers a variety of methods that involve use of restriction enzymes to generate differential gene-expression patterns.
The new patent broadens protection for Gene Logic's Restriction Enzyme Analysis of Differentially Expressed Sequences display technology, the basis for the company's largest revenue-generating business.